214 related articles for article (PubMed ID: 28832866)
1. Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
Eng OS; Dumitra S; O'Leary M; Raoof M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Paz IB; Lee B
JAMA Surg; 2017 Dec; 152(12):1156-1160. PubMed ID: 28832866
[TBL] [Abstract][Full Text] [Related]
2. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Eng OS; Dumitra S; O'Leary M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Benjamin Paz I; Singh G; Lee B
Ann Surg Oncol; 2017 Sep; 24(9):2707-2711. PubMed ID: 28560593
[TBL] [Abstract][Full Text] [Related]
3. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
4. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures.
Foster JM; Sleightholm R; Patel A; Shostrom V; Hall B; Neilsen B; Bartlett D; Smith L
JAMA Netw Open; 2019 Jan; 2(1):e186847. PubMed ID: 30646202
[TBL] [Abstract][Full Text] [Related]
5. Restrictive Intraoperative Fluid Therapy is Associated with Decreased Morbidity and Length of Stay Following Hyperthermic Intraperitoneal Chemoperfusion.
Hendrix RJ; Damle A; Williams C; Harris A; Spanakis S; Lambert DH; Lambert LA
Ann Surg Oncol; 2019 Feb; 26(2):490-496. PubMed ID: 30515670
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
7. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
8. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
9. Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.
Dazza M; Schwarz L; Coget J; Frebourg N; Wood G; Huet E; Bridoux V; Veber B; Tuech JJ
World J Surg; 2016 Dec; 40(12):3035-3043. PubMed ID: 27412631
[TBL] [Abstract][Full Text] [Related]
10. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
[TBL] [Abstract][Full Text] [Related]
12. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
15. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
16. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
Lee L; Alie-Cusson F; Dubé P; Sideris L
J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
[TBL] [Abstract][Full Text] [Related]
17. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
19. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
20. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Chua TC; Quinn LE; Zhao J; Morris DL
J Surg Oncol; 2013 Aug; 108(2):81-8. PubMed ID: 23737041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
